Guidant (Indianapolis) said in mid-December that it had begun enrollment in the Japan arm of its SPIRIT III drug-eluting stent clinical trial, which is evaluating Xience V, an everolimus-eluting coronary stent system that uses Guidant's cobalt chromium Multi-Link Vision coronary stent system rapid-exchange platform.